Pergoveris Heads for Fast-Track FDA Review
EMD Serono revealed it will seek FDA priority review for its fertility drug Pergoveris under the National Priority Voucher program, aligning with Trump’s broader effort to expedite access to critical health innovations.
The White House confirmed that Pergoveris will be among the first drugs accepted into the program.
Part of Trump’s “Most Favored Nation” Pricing Agenda
The IVF initiative marks the third major deal under Trump’s “most favored nation” drug pricing program, aimed at aligning U.S. medication prices with global lows.
In September, Pfizer agreed to similar terms for Medicaid drugs and direct consumer sales through TrumpRx.gov, while AstraZeneca reached a Medicaid discount deal earlier this month. Both companies secured tariff exemptions in return for lowering costs and investing in U.S. manufacturing.
All three pharmaceutical giants—Pfizer, AstraZeneca, and now EMD Serono—will feature discounted medications on TrumpRx.gov, slated to launch in January 2026.
